Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
Condition: Anemia Interventions: Drug: Vadadustat; Drug: Darbepoetin alfa Sponsors: Akebia Therapeutics; Otsuka Pharmaceutical Development& Commercialization, Inc. (OPDC) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials